#ESMO17: AstraZeneca salves stinging setback with a big win in a blockbuster segment of the lung cancer market
MADRID — Just weeks after AstraZeneca was hammered by a round-one failure for its checkpoint combo on non-small cell lung cancer, the pharma giant repaired some of that damage at ESMO with an impressive hit for a blockbuster market segment.
Tackling stage 3 lung cancer, AstraZeneca’s top execs turned up in Madrid to unveil data from their PACIFIC trial which revealed a progression-free survival advantage of more than 11 months for a group of patients taking Imfinzi (durvalumab) over placebo— 16.8 versus 5.6 months. That represents a 48% drop in the risk of progression.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.